Pedro Castelo-Branco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4049146/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
2	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
3	Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	1.6	381
4	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	1.6	244
5	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncology, The, 2013, 14, 534-542.	10.7	212
6	Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. Journal of Biomedical Science, 2018, 25, 22.	7.0	172
7	Polypyrimidine Tract Binding Protein Modulates Efficiency of Polyadenylation. Molecular and Cellular Biology, 2004, 24, 4174-4183.	2.3	155
8	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	8.2	130
9	Cellular Interactions in the Tumor Microenvironment: The Role of Secretome. Journal of Cancer, 2019, 10, 4574-4587.	2.5	91
10	Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers. BMC Cancer, 2019, 19, 219.	2.6	90
11	Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects. Molecular Therapy, 2008, 16, 1041-1047.	8.2	74
12	Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy. Urologia Internationalis, 2017, 99, 125-136.	1.3	61
13	Combined genetic and epigenetic alterations of the <i>TERT</i> promoter affect clinical and biological behavior of bladder cancer. International Journal of Cancer, 2019, 144, 1676-1684.	5.1	57
14	Monoallelic Expression Determines Oncogenic Progression and Outcome in Benign and Malignant Brain Tumors. Cancer Research, 2012, 72, 636-644.	0.9	56
15	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 57726-57736.	1.8	55
16	Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition. Clinical Cancer Research, 2011, 17, 111-121.	7.0	53
17	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathologica, 2014, 128, 853-862.	7.7	46
18	Telomere dysfunction and chromothripsis. International Journal of Cancer, 2016, 138, 2905-2914.	5.1	42

#	Article	IF	CITATIONS
19	Epigenetic Profiling in Severe Sepsis: A Pilot Study of DNA Methylation Profiles in Critical Illness*. Critical Care Medicine, 2020, 48, 142-150.	0.9	42
20	Epigenetics of Sepsis. Critical Care Medicine, 2020, 48, 745-756.	0.9	41
21	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 174.	5.2	37
22	Epigenetic therapy in urologic cancers: an update on clinical trials. Oncotarget, 2017, 8, 12484-12500.	1.8	35
23	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathologica, 2014, 128, 863-877.	7.7	34
24	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. Immunotherapy, 2016, 8, 1011-1019.	2.0	34
25	New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. Journal of Clinical Medicine, 2020, 9, 3543.	2.4	28
26	Lung cancer: a brief review of epidemiology and screening. Future Oncology, 2018, 14, 567-575.	2.4	24
27	CRISPR-based strategies in infectious disease diagnosis and therapy. Infection, 2021, 49, 377-385.	4.7	19
28	The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer. Future Oncology, 2017, 13, 2045-2051.	2.4	17
29	Current and potential biomarkers in gastric cancer: a critical review of the literature. Future Oncology, 2021, 17, 3383-3396.	2.4	16
30	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers, 2022, 14, 122.	3.7	16
31	Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression. Aging, 2021, 13, 21991-22029.	3.1	15
32	MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway. Journal of Thoracic Disease, 2018, 10, S2076-S2078.	1.4	11
33	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	11
34	Homologous gene sequences mediate transcription-domain formation. Journal of Cell Science, 2006, 119, 3876-3887.	2.0	10
35	Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget, 2018, 9, 11805-11815.	1.8	9
36	Screening for Colorectal Cancer Leading into a New Decade: The "Roaring â€~20s―for Epigenetic Biomarkers?. Current Oncology, 2021, 28, 4874-4893.	2.2	9

Pedro Castelo-Branco

#	Article	IF	CITATIONS
37	Marine Natural Products as a Promising Source of Therapeutic Compounds to Target Cancer Stem Cells. Current Medicinal Chemistry, 2021, 28, 4343-4355.	2.4	8
38	Promises and challenges of exhausting pediatric neural cancer stem cells. Pediatric Research, 2012, 71, 523-528.	2.3	6
39	Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?. Translational Lung Cancer Research, 2020, 9, 2311-2314.	2.8	6
40	PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?. Future Oncology, 2019, 15, 1407-1410.	2.4	4
41	Current advances in targeted therapies for metastatic gastric cancer: improving patient care. Future Oncology, 2016, 12, 839-854.	2.4	3
42	What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 249-261.	3.8	3
43	DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study. Cancers, 2021, 13, 6354.	3.7	3
44	Hot topics in epigenetic regulation of cancer self-renewal for pancreatic tumors: future trends. Future Oncology, 2019, 15, 683-685.	2.4	2
45	Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. Perspective Journal of Clinical Oncology, 2020, 38, 689-689.	1.6	2
46	Epigenetic regulation of cancer self-renewal differs between endocrine tumors Journal of Clinical Oncology, 2017, 35, e15717-e15717.	1.6	0
47	Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients Journal of Clinical Oncology, 2018, 36, 546-546.	1.6	Ο
48	Post-transcriptional silencing of Bos taurus prion family genes and its impact on granulosa cell steroidogenesis. Biochemical and Biophysical Research Communications, 2022, 598, 95-99.	2.1	0
49	Correction for: Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression. Aging, 2022, 14, 2014-2015.	3.1	0